ImmuCell (NASDAQ:ICCC) Shares Cross Above 200-Day Moving Average – Should You Sell?

ImmuCell Co. (NASDAQ:ICCC) shares crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $4.61 and traded as high as $5.55. ImmuCell shares last traded at $5.39, with a volume of 65,701 shares trading hands.

ImmuCell Trading Up 0.2 %

The company has a quick ratio of 1.44, a current ratio of 3.11 and a debt-to-equity ratio of 0.36. The business’s 50 day moving average is $5.08 and its two-hundred day moving average is $4.61. The firm has a market capitalization of $49.41 million, a P/E ratio of -11.00 and a beta of 0.39.

ImmuCell (NASDAQ:ICCC) last issued its quarterly earnings results on Tuesday, February 25th. The biotechnology company reported $0.06 EPS for the quarter. The firm had revenue of $7.75 million for the quarter. ImmuCell had a negative net margin of 15.99% and a negative return on equity of 15.32%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Mesirow Financial Investment Management Inc. increased its stake in shares of ImmuCell by 100.0% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company’s stock worth $125,000 after purchasing an additional 12,178 shares during the last quarter. Citadel Advisors LLC acquired a new position in ImmuCell during the fourth quarter worth $149,000. Northern Trust Corp raised its holdings in ImmuCell by 51.0% during the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company’s stock valued at $229,000 after buying an additional 14,982 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of ImmuCell by 13.9% in the fourth quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company’s stock worth $332,000 after buying an additional 7,878 shares during the last quarter. Finally, Dauntless Investment Group LLC bought a new stake in shares of ImmuCell during the 4th quarter worth about $676,000. Hedge funds and other institutional investors own 13.47% of the company’s stock.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.